[email protected]/(408) 457-3700

About ArtGen Inc.

Artgen Inc. was incorporated in Delaware in 2014 in order to bring Neovaculgen therapy to approval in the United States and the rest of the world outside of outside of the Russian Federation and the Commonwealth of Independent States (CIS). Artgen has exclusive rights to the Neovasculgen patent estate owned by Human Stem Cell Institute (http://eng.hsci.ru/home) for territories, including the United States and Canada. Artgen is located in the Germantown, MD Innovation Center, a biotech incubator run by the State of Maryland. Neovasculgen was developed in Russia by Human Stem Cell Institute (HSCI), the first biotech company in Russia to go public. HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services. HSCI launched a Russia-wide network of advanced medical genetics centers under the Genetico brand (genetic screening, pre-implantation genetic diagnosis, non-invasive prenatal testing, reproductive tissue bank services, etc.). It also launched the first in Russia Lab & Production Complex for the development of new products and services in the fields of regenerative medicine and medical genetics. HSCI became a co-investor in SynBio, a multilateral international project supported by RUSNANO to develop novel medicines (first-in-class and BioBetters) for the Russian and global markets. It acquired a 50% stake in Hemafund, the largest family сord blood bank in Ukraine and launched a family of cord blood banks called Gemabank, the largest in Russia. In 2009 HSCI had an IPO on the MICEX index, becoming the first Russian biotech to go public (ticker: ISKJ). Launched by HSCI, Neovasculgen was the first approved gene therapy in the world for peripheral artery disease, including critical limb ischemia. HSCI was granted marketing authorization in Russia for Neovasculgen® in December 2011 (Registration Certificate No.LP-000671) and in Ukraine in February 2013 (Registration Certificate No.899/13-00200000). Neovasculgen® has been shown to improve pain-free walking distance (PFWD), a mean change in absolute claudication distance from baseline of 135.3 meters up to a mean distance of 393.4 meters (2.9X improvement) at 24 months. It is suggested that the drug's mechanism of action can provide an even longer effect – post-marketing follow-up will continue over the course of five years from the initial treatment.

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

Biotechnology, Pharmaceuticals
Therapeutic Areas:
Vascular Diseases